Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant ReviewBusiness Wire • Wednesday
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/05/24
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire • 03/05/24
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024Business Wire • 02/20/24
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire • 02/16/24
Wall Street Analysts Think Marinus Pharmaceuticals (MRNS) Could Surge 113.01%: Read This Before Placing a BetZacks Investment Research • 01/17/24
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business UpdateBusiness Wire • 01/04/24
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD StudyBusiness Wire • 11/20/23
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx ConferenceBusiness Wire • 11/14/23
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsBusiness Wire • 11/07/23
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CVBusiness Wire • 11/07/23
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023Business Wire • 10/24/23
Wall Street Analysts Believe Marinus Pharmaceuticals (MRNS) Could Rally 183.33%: Here's is How to TradeZacks Investment Research • 10/11/23
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare ConferenceBusiness Wire • 09/21/23
Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/20/23
Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst EventBusiness Wire • 09/19/23
Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023Business Wire • 09/12/23
Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023Business Wire • 08/17/23
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/10/23